Diabetes and the treatment of ischemic stroke |
| |
| Affiliation: | 1. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA;2. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA;1. Endocrinology, Diabetes and Metabolism Institute, Cleveland Clinic, Cleveland, OH 44195, United States of America;2. Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, United States of America;1. Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, Serbia;2. Medical Faculty, University of Novi Sad, Novi Sad, Serbia;3. Faculty of Medicine, Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;4. Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece;1. Department of Internal Medicine, Division of General Medicine, University of California, Davis Medical Center, Sacramento, CA, United States of America;2. Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of California, Davis Medical Center, Sacramento, CA, United States of America;3. Endocrine Section, Medicine Service, Sacramento VA Medical Center, Mather, CA, United States of America;1. Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, United States of America;2. Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States of America;3. Houston Methodist Hospital, Houston, TX, United States of America |
| |
| Abstract: | This white paper examines the current challenges for treating ischemic stroke in diabetic patients. The need for a greater understanding of the mechanisms that underlie the relationship between diabetes and the cerebral vascular responses to ischemia is discussed. The critical need to improve the efficacy and safety of thrombolysis is addressed, as is the need for a better characterization the off-target actions of tPA, the only currently approved thrombolytic for the treatment of ischemic stroke. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
